Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Robin Brammer

Internal Medicine Milford, CT Doctor of Osteopathy

NPI 1275575995 CMS profile 148172

234 Broad St, Milford Physician Services Pc, Milford, CT 06460

Open in the dashboard

General payments

$3,275

176 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Robin Brammer of Milford, CT is reported in the CMS Open Payments database as having received $3,275 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $326 18
2021 General $1,412 69
2020 General $674 37
2019 General $862 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Brammer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robin Brammer were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robin Brammer Internal Medicine median Middle half National median
2019 $862 $159 $48–$570 $163
2020 $674 $119 $33–$402 $114
2021 $1,412 $135 $37–$521 $132
2022 $326 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $861 41 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $637 31 payments
  3. AstraZeneca Pharmaceuticals LP $294 18 payments
  4. Lilly USA, LLC $276 16 payments
  5. Mylan Specialty L.P. $266 15 payments
  6. Merck Sharp & Dohme Corporation $128 8 payments
  7. OptiNose US, Inc. $86 5 payments
  8. Jazz Pharmaceuticals Inc. $75 5 payments
  9. Philips Electronics North America Corporation $74 5 payments
  10. Advanced Respiratory, Inc $59 3 payments
  11. Other $520 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,275 176 payments
Products named General payments · program years 2019–2022
  1. OFEV $417 17 payments
  2. TRELEGY ELLIPTA $396 12 payments
  3. SPIRIVA RESPIMAT $277 17 payments
  4. TRULICITY $264 15 payments
  5. JARDIANCE $264 15 payments
  6. Yupelri $176 10 payments
  7. Perforomist $176 10 payments
  8. ANORO ELLIPTA $163 10 payments
  9. NUCALA $158 10 payments
  10. BREZTRI $123 7 payments
  11. Other $2,112 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record